Biogen Idec (NASDAQ: [[ticker:BIIB]]) of Cambridge, MA, and Ireland’s Elan announced this afternoon that the FDA has granted an expanded approval for their drug Tysabri as a treatment for Crohn’s disease. The drug was previously approved to treat multiple sclerosis.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
